Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Inc (ELAN) news coverage tracks developments from one of the global animal health industry's major players. As a company serving both the companion animal and farm animal markets, Elanco generates news across multiple fronts: FDA approvals and regulatory decisions for veterinary pharmaceuticals, quarterly and annual financial results, product launches in parasiticide and dermatology categories, and strategic transactions that shape the animal health competitive landscape.
Investors following Elanco monitor announcements related to the company's pipeline of veterinary drugs and treatments. Regulatory milestones, including new drug approvals, label expansions, and emergency use authorizations, can significantly impact the company's market position in key therapeutic categories. Clinical development updates provide visibility into future revenue opportunities across companion animal and livestock health segments.
Financial news for Elanco includes quarterly earnings reports detailing performance across geographic regions and business segments. The companion animal segment, driven by pet ownership trends and veterinary spending, often shows different dynamics than the farm animal business, which correlates with agricultural commodity cycles and protein consumption patterns. Understanding both segments provides context for evaluating the company's overall trajectory.
Corporate news covers strategic initiatives such as licensing agreements, acquisitions, and partnerships that expand Elanco's product portfolio or geographic reach. The animal health industry experiences ongoing consolidation and innovation, making transaction announcements and research collaborations relevant for assessing competitive positioning. Bookmark this page to follow Elanco news as regulatory decisions, financial results, and strategic developments unfold.
Elanco Animal Health reported a 27% increase in third quarter revenue, reaching $1,131 million, boosted by the Bayer Animal Health acquisition. The company updated its full-year revenue guidance to $4,730 to $4,770 million while maintaining adjusted EPS guidance of $0.97 to $1.03. However, reported EPS was $(0.21). Gross margin improved significantly to 55.6%. Elanco's operational performance reflected strong fundamentals, particularly in the Farm Animal and Pet Health sectors, with significant product contributions. The company anticipates continued growth in 2022.
Elanco Animal Health (NYSE: ELAN) has been recognized in FORTUNE’s 2021 Change the World list, ranking 19th among 53 companies making a social or environmental impact. This accolade highlights Elanco's East Africa Growth Accelerator (EAGA), which supports smallholder farmers in Tanzania, Kenya, and Uganda by providing affordable veterinary products and training. The initiative, begun in 2017 with backing from the Bill & Melinda Gates Foundation, integrates into Elanco's operations, emphasizing animal health's role in addressing hunger and climate challenges.
Elanco Animal Health (NYSE: ELAN) is set to announce its third quarter 2021 financial results on November 5, 2021. A conference call will follow at 8:00 a.m. eastern time to discuss the company's performance, accessible via a live webcast on Elanco's website. The company specializes in products and services aimed at preventing and treating diseases in farm animals and pets, emphasizing sustainability and community impact. With nearly 70 years of experience in animal health, Elanco aims to improve the welfare of animals globally.
Elanco Animal Health (NYSE: ELAN) announces the appointment of Ellen de Brabander, Ph.D., as the new executive vice president of Innovation and Regulatory Affairs, effective October 18. She brings extensive experience, including leading the development of NexGard. The company maintains its innovation revenue expectations of $600 to $700 million by 2025, driven by the acquisition of KindredBio and ongoing pipeline advancements. Additionally, Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform to establish an independent biopharmaceutical entity.
Elanco Animal Health has completed the acquisition of Kindred Biosciences for
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021. CEO Jeff Simmons will join a virtual fireside chat at 3:30 p.m. ET. Investors can access a live audio webcast on Elanco's investor website, with a replay available for 90 days.
Elanco is a leader in animal health, focusing on innovative solutions for the well-being of farm animals and pets. With nearly 70 years of experience, they aim to enhance animal health and contribute positively to communities worldwide.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
